Novartis Reportedly Taps Centerview to Evaluate Options for Dermatology Business

Drug manufacturer Novartis AG (NVS) has hired Centerview Partners LLC to help evaluate options for its dermatology unit, including a potential sale, Reuters reported on Thursday, Nov. 2.

The report came on the heels of a Bloomberg article on Wednesday stating that Switzerland-headquartered Novartis was mulling a sale of the dermatology generics drug business, which is primarily based in the U.S. The unit could be valued at between $1 billion to $1.5 billion,  Bloomberg reported.

A Novartis representative said the company does not comment on speculation.

Novartis' American depository receipts closed at $82.78 on Thursday, up 0.01%.

On Oct. 24, Novartis unveiled third-quarter results that topped estimates and said a possible spin off of its Alcon eyecare division was not likely before 2019.

Novartis reported sales of $12.4 billion, slightly higher than analysts' expectations, while core operating income was up 1% in constant currencies at $2.4 billion.

Net income was up 7% in the three months to the end of September to $2.08 billion from last year's $1.95 billion. Earnings per share grew 10% to $0.89 from $0.81 a year ago.

Analysts surveyed by FactSet had expected net income for the quarter of $2.02 billion and sales of $12.34 billion.

Novartis on Oct. 30 said it was buying French drugmaker Advanced Accelerator Applications SA  (AAAP) for $3.9 billion in a deal to strengthen its oncology businesses.

—Lisa Botter contributed to this report

More of What's Trending on TheStreet:

More from Stocks

Stocks Dive Globally as U.S.-China Trade War Intensifies

Stocks Dive Globally as U.S.-China Trade War Intensifies

5 Stock Picks Under $10 for Millennials

5 Stock Picks Under $10 for Millennials

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know

Chart Professor: 3 Things You Need to Know About Every Stock Chart

Chart Professor: 3 Things You Need to Know About Every Stock Chart

Surprising Reasons Airline Stocks May Surge Even If There Are Ticket Price Wars

Surprising Reasons Airline Stocks May Surge Even If There Are Ticket Price Wars